Liver Pub Date : 1995-08-01 DOI: 10.1111/j.1600-0676.1995.tb00668.x

K Kanai, M Kako, T Aikawa, T Kumada, T Kawasaki, T Hatahara, Y Oka, M Mizokami, T Sakai, K Iwata

引用次数: 14

Primary biliary cirrhosis: lung involvement. 原发性胆汁性肝硬化:累及肺部。

Liver Pub Date : 1995-08-01 DOI: 10.1111/j.1600-0676.1995.tb00670.x

C Costa, A Sambataro, S Baldi, V Modena, L Todros, D Libertucci, F Coni, E Fusaro, F Revello, A Murgia

{"title":"Primary biliary cirrhosis: lung involvement.","authors":"C Costa, A Sambataro, S Baldi, V Modena, L Todros, D Libertucci, F Coni, E Fusaro, F Revello, A Murgia","doi":"10.1111/j.1600-0676.1995.tb00670.x","DOIUrl":"https://doi.org/10.1111/j.1600-0676.1995.tb00670.x","url":null,"abstract":"Sub-clinical lung impairment, mostly represented by a reduced diffusion of alveolar gases, is a recognised complication of advanced primary biliary cirrhosis. The aim of the study was to evaluate the prevalence and type of pulmonary involvement in primary biliary cirrhosis and the relationship between lung function abnormalities and selected epidemiological and clinical variables. Sixty-one patients with different stages of primary biliary cirrhosis consecutively seen in our outpatient clinic were evaluated. The advancement of primary biliary cirrhosis was characterised by the histological stage, the presence of signs of portal hypertension and the Mayo Risk Score: a Cox regression model using serum bilirubin and albumin levels, prothrombin time, age and degree of oedema as selected variables. We measured static and dynamic lung volumes, by means of a spirometer, and diffusing capacity for carbon monoxide. Rheumatological disorders were evaluated by an independent rheumatologist. No patient complained of respiratory symptoms. Airway obstruction was present in one patient. In 24 patients (39%) the alveolar diffusion capacity was reduced. We did not find any significant relationship between diffusing capacity and smoking habits, advancement of liver disease and concomitant Sjogren syndrome. Reduced diffusion capacity showed a significant correlation with the presence of complete or incomplete CREST syndrome (p < 0.01) and with the presence of circulating anti-centromere antibodies (p < 0.05). Alveolar diffusion capacity is frequently impaired in patients with primary biliary cirrhosis, usually in the absence of clinical manifestations. These alterations mostly affect patients with concomitant CREST syndrome.(ABSTRACT TRUNCATED AT 250 WORDS)","PeriodicalId":18183,"journal":{"name":"Liver","volume":"15 4","pages":"196-201"},"PeriodicalIF":0.0,"publicationDate":"1995-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1600-0676.1995.tb00670.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19524410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Manifestation late in life of idiopathic adulthood ductopenia. 特发性成年ductopia的晚期表现。

Liver Pub Date : 1995-08-01 DOI: 10.1111/j.1600-0676.1995.tb00673.x

C Müller, W Ulrich, E Penner

引用次数: 14

Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects. 意大利静脉注射吸毒者丙型肝炎病毒感染:流行病学和临床方面。

Liver Pub Date : 1995-08-01 DOI: 10.1111/j.1600-0676.1995.tb00672.x

B Galeazzi, A Tufano, E Barbierato, F Bortolotti

{"title":"Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects.","authors":"B Galeazzi, A Tufano, E Barbierato, F Bortolotti","doi":"10.1111/j.1600-0676.1995.tb00672.x","DOIUrl":"https://doi.org/10.1111/j.1600-0676.1995.tb00672.x","url":null,"abstract":"The epidemological and clinical features of hepatitis C virus infection have been evaluated in a cohort of 227 intravenous drug users enrolled at a drug dependence treatment center in the Veneto area in 1992-1993 and followed periodically. Hepatitis C virus infection was detected using second-generation anti-HCV ELISA in 171 (75%) subjects at enrollment. Anti-HCV seropositivity correlated with: a) the duration of drug abuse: 91% of intravenous drug users injecting for more than 8 years were seropositive as compared to 40% of those with a history of abuse lasting 4 years or less, p < 0.001; b) sharing of injection equipment: 85% anti-HCV positive intravenous drug users had shared at some time as compared to 64% seronegative subjects, p < 0.001; c) seropositivity for immunodeficiency virus infection: 25% anti-HCV positive intravenous drug users were coinfected as compared to 3.5% anti-HCV negative, p < 0.001; d) markers of ongoing (two cases) or previous hepatitis B virus infection were detected in 62% of anti-HCV positive but in 21% of anti-HCV negative cases, p < 0.01. Two initially anti-HCV negative intravenous drug users seroconverted during follow up giving an incidence rate of hepatitis C virus infection of 6.2 per 100 person-years. During the survey abnormal alanine aminotransferase levels were detected in 75% anti-HCV positive but in 24% anti-HCV negative cases (p < 0.001), with significantly higher levels in the former. These findings suggest that the circulation of hepatitis C virus among intravenous drug users has been decreasing in recent years, although new infections still occur.(ABSTRACT TRUNCATED AT 250 WORDS)","PeriodicalId":18183,"journal":{"name":"Liver","volume":"15 4","pages":"209-12"},"PeriodicalIF":0.0,"publicationDate":"1995-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1600-0676.1995.tb00672.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19524412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 61

Hepatocyte and Kupffer cell function after liver transplantation in the rat--in vivo evaluation with dynamic scintigraphy. 大鼠肝移植后肝细胞和库普弗细胞功能的动态显像评价。

Liver Pub Date : 1995-08-01 DOI: 10.1111/j.1600-0676.1995.tb00669.x

G Svensson, S Friman, L Jacobsson, S B Holmberg

{"title":"Hepatocyte and Kupffer cell function after liver transplantation in the rat--in vivo evaluation with dynamic scintigraphy.","authors":"G Svensson, S Friman, L Jacobsson, S B Holmberg","doi":"10.1111/j.1600-0676.1995.tb00669.x","DOIUrl":"https://doi.org/10.1111/j.1600-0676.1995.tb00669.x","url":null,"abstract":"In vivo physiological measurements of hepatocyte and Kupffer cell function after liver transplantation are desirable. Orthotopic liver transplantation was performed in 54 rats. Hepatocyte and Kupffer cell function were measured with dynamic liver scintigraphy. Hepatic clearance of 99mTc-Nanocoll (%/min), an albumin colloid phagocytosed by the Kupffer cells, was used to evaluate Kupffer cell function. Hepatic clearance of 99mTc-IODIDA (%/min), an imino-diacetic-acid taken up and secreted by the hepatocytes, was used to evaluate the hepatocyte function. Hepatic clearance in control rats was 27 +/- 2%/min for Nanocoll and 30 +/- 3 %/min for IODIDA. After syngenic liver transplantation, without rejection, there was a rise in Nanocoll clearance (34 +/- 2 %/min p < 0.01) after 3 weeks, but no change in IODIDA clearance (32 +/- 3 %/min N.S.). After syngenic liver transplantation with preservation time prolonged to 16 h, there were no changes in IODIDA or Nanocoll clearance 1 day after transplantation. Both IODIDA (11 +/- 2 %/min) and Nanocoll clearance (22 +/- 2 %/min) were decreased (p < 0.001) during rejection after allogenic transplantation. An in vivo method of measuring the hepatocyte and Kupffer cell function in the transplanted liver is described. Kupffer cell function was increased after syngenic liver transplantation. Kupffer cell and hepatocyte function were decreased during rejection. Dynamic liver scintigraphy seems a suitable procedure for examining liver injury after liver transplantation in the experimental setting.","PeriodicalId":18183,"journal":{"name":"Liver","volume":"15 4","pages":"189-95"},"PeriodicalIF":0.0,"publicationDate":"1995-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1600-0676.1995.tb00669.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19524409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Testing for hepatitis C virus sequences in peripheral blood mononuclear cells of patients with chronic hepatitis C in the absence of serum hepatitis C virus RNA. 血清丙型肝炎病毒RNA缺失情况下慢性丙型肝炎患者外周血单个核细胞丙型肝炎病毒序列检测

Liver Pub Date : 1995-04-01

L Muratori, F Giostra, M Cataleta, R Francesconi, G Ballardini, F Cassani, M Lenzi, F B Bianchi

引用次数: 0

Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities. 与苯扎酮有关的严重肝毒性:3例报告，2例死亡。

Liver Pub Date : 1995-02-01 DOI: 10.1111/j.1600-0676.1995.tb00102.x

M L Hautekeete, J Henrion, S Naegels, A DeNeve, M Adler, C Deprez, G Devis, G Klöppel

引用次数: 39

Association of primary sclerosing cholangitis, thymoma and hypogammaglobulinemia. 原发性硬化性胆管炎、胸腺瘤和低丙种球蛋白血症的关系。

Liver Pub Date : 1995-02-01 DOI: 10.1111/j.1600-0676.1995.tb00107.x

R Yoshioka, Y Sato, A Kogure, H Ohira, T Takagi, M Kuroda, M Miyata, K Obara, T Nishimaki, R Kasukawa

引用次数: 11

Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses. 淋巴母细胞样干扰素治疗慢性丙型肝炎:两种不同剂量的生化、病毒学和组织学评价。

Liver Pub Date : 1995-02-01 DOI: 10.1111/j.1600-0676.1995.tb00101.x

A Picciotto, F Callea, G Varagona, E Bardellini, S Borzone, V De Conca, E Vallarino, A Giudici-Cipriani, A Vitali, A Grasso

{"title":"Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses.","authors":"A Picciotto, F Callea, G Varagona, E Bardellini, S Borzone, V De Conca, E Vallarino, A Giudici-Cipriani, A Vitali, A Grasso","doi":"10.1111/j.1600-0676.1995.tb00101.x","DOIUrl":"https://doi.org/10.1111/j.1600-0676.1995.tb00101.x","url":null,"abstract":"Sixty patients of both sexes with biopsy-proven chronic hepatitis C were randomized to receive lymphoblastoid interferon 3 MU or 6 MU three times weekly for 6 months. A follow-up period of 3 months at the end of the therapy was scheduled. Thirty-two patients (53.3%) normalized alanine aminotransferase at the end of the therapy. Of these, 17 received 3 MU (56.7%) and 15 (50%) received 6 MU. Eighteen of the 32 patients (56.2%) relapsed in the follow-up period after treatment. No significant difference in relapse rate was observed between the two groups. The overall percentage of the non-responder patients was 36.6%. The treatment was discontinued because of non-compliance and/or side effects in six patients (10%): three in the 3-MU group and three in the 6-MU group. An improvement in liver histology was observed in about a quarter of chronic active hepatitis patients whose overall diagnosis changed to chronic persistent hepatitis. Knodell's score system showed a significant improvement (p < 0.05) with regard to peripheral necrosis, fibrosis and total score. HCV-RNA was positive at the beginning in all patients and it became undetectable in almost all responder patients. In some cases there was no correlation between viraemia and biochemical signs of liver disease. Our study shows that 6 MU does not increase the response rate compared to 3 MU. Moreover, the lower dose is able to improve the liver histology and to abolish the HCV viraemia in responder patients.","PeriodicalId":18183,"journal":{"name":"Liver","volume":"15 1","pages":"20-4"},"PeriodicalIF":0.0,"publicationDate":"1995-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1600-0676.1995.tb00101.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18780034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. 法国用12个月疗程的干扰素治疗慢性D型肝炎的经验。随机对照试验结果。

Liver Pub Date : 1995-02-01 DOI: 10.1111/j.1600-0676.1995.tb00106.x

J L Gaudin, P Faure, H Godinot, F Gerard, C Trepo

{"title":"The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial.","authors":"J L Gaudin, P Faure, H Godinot, F Gerard, C Trepo","doi":"10.1111/j.1600-0676.1995.tb00106.x","DOIUrl":"https://doi.org/10.1111/j.1600-0676.1995.tb00106.x","url":null,"abstract":"Hepatitis due to hepatitis delta virus (HDV) infection is generally associated with severe histological abnormalities and rapid progression of the disease. To assess the efficacy of recombinant interferon-a2b in treatment of chronic delta hepatitis, 22 patients were entered into a randomized controlled trial: 11 received interferon-a2b subcutaneously three times weekly for 12 months (5 MU/m2 for 4 months and then 3 MU/m2 for a further 8 months) and 11 were untreated. All patients were followed up for 6 months after the completion of therapy. Nine treated patients completed the trial: one was withdrawn with hyperthyroidism and one committed suicide. Serum ALT levels were normalized or significantly reduced, always within 3 months of initiating treatment, and remained so in 73% of treated patients at the 4th month and in 54.5% at the 12th month, compared with 18% and 18%, respectively, in the untreated group. Moreover, in seven of nine treated patients, interferon was associated with the clearance of serum HDV-RNA, associated with amelioration of the histological picture, whereas this occurred in only four of 11 untreated patients. On cessation of therapy, all patients but one experienced a biological and/or virological relapse over the 6-month follow up. In conclusion, our data confirm that HDV is sensitive to inhibition by interferon-a2b, although the schedule used did not achieve permanent control of the disease. The adverse effects of interferon require consideration; in particular, care will be needed to avoid serious psychiatric side effects.","PeriodicalId":18183,"journal":{"name":"Liver","volume":"15 1","pages":"45-52"},"PeriodicalIF":0.0,"publicationDate":"1995-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1600-0676.1995.tb00106.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18780038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 61

Liver最新文献